

Development of next-generation cancer immunotherapy via FAP-targeted IL-12 attenuation-based TMEkine™

KANAPH Therapeutics Inc.



ONCOLOGY	Candidate
Product Type	Immunocytokine (bispecific cytokine Fc-fusion protein)
Indication	Solid tumors including NSCLC which have high expression of FAP(Fibroblast Activation Protein)
Target	Second line treatment in combination with checkpoint inhibitors in NSCL patients
MoA(Mechanism of Action)	Immunocytokine comprising anti-FAP and attenuated IL-12 (internally named KNP-101) <ul style="list-style-type: none"> • Anti-FAP for TME (tumor microenvironment) targeting • IL-12 attenuation for reduced toxicity and wide therapeutic window
Competitiveness	There are no companies that is working on a dual approach which utilizes an attenuated IL-12 and a tumor targeting arm. We believe that this is the biggest differentiating factor compared to our competitors as we can generate a more efficacious, yet less toxic therapy for maximizing therapeutic window.
Development Stage	Candidate
Route of Administration	Intravenous or subcutaneous administration